Interim report 1 January - 31 March 2009
Three months ended 31 March 2009
§ Local currency sales increased by 21% and Euro sales increased by
6%, to ¤341.3m (¤321.8m).
§ Average size of the sales force increased by 19%, to 3.1m
consultants and closing sales force was up by 25%.
§ EBITDA amounted to ¤43.3m (¤57.2m).
§ Operating margin was 11.1% (15.6%) resulting in an operating
profit of ¤37.9m (¤50.2m).
§ Net profit amounted to ¤24.2m (¤37.9m).
§ EPS after dilution amounted to ¤0.43 (¤0.67).
§ Cash flow from operating activities amounted to ¤12.6m (¤3.3).
§ Oriflame agreed a ¤130m three-year term loan and revolving credit
facility with its core banks
§ New outlook for 2009: Sales growth is expected to be well above
10% in local currency. The margin target remains and is expected to
be around 11% at the prevailing exchange rates.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.